Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a medicaid population: A retrospective cohort analysis

BMC Pediatrics

Volumn 14, Issue 1, 2014, Pages 1-11

  Krilov, Leonard R ^a,b   Masaquel, Anthony S ^c   Weiner, Leonard B ^d   Smith, David M ^e   Wade, Sally W ^f   Mahadevia, Parthiv J ^c  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c MEDIMMUNE   (United States)

^d SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^e IBM WATSON HEALTH   (United States)

^f Wade Outcomes Research and Consulting   (United States)

Author keywords

Non compliance; Palivizumab; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; CHRONIC LUNG DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAID; POPULATION RISK; PREMATURITY; PROPHYLAXIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; AGE; ANCESTRY GROUP; CHEMOPROPHYLAXIS; DRUG ADMINISTRATION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RURAL POPULATION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGE FACTORS; ANTIVIRAL AGENTS; CHEMOPREVENTION; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; INFANT; LOGISTIC MODELS; MALE; MEDICAID; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RURAL POPULATION; SEX FACTORS; UNITED STATES;

EID: 84928802458     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-14-261     Document Type: Article

References (17)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999, 282(15):1440-1446.
2. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ: A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010, 16(1):46-58.
3. Diehl JL, Daw JR, Coley KC, Rayburg R: Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. J Manag Care Pharm 2010, 16(1):23-31.
4. Paramore LC, Ciuryla V, Ciesla G, Liu L: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004, 22(5):275-284.
5. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000, 137(6):865-870.
6. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M: Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008, 28(7):511-517.
7. Sangare L, Curtis MP, Ahmad S: Hospitalization for respiratory syncytial virus among California infants: disparities related to race, insurance, and geography. J Pediatr 2006, 149(3):373-377.
8. The Impact RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. the IMpact-RSV Study Group. Pediatrics 1998, 102(3 Pt 1):531-537.
9. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143(4):532-540.
10. Hampp C, Saidi AS, Winterstein AG: Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr 2010, 156(6):953-959. 959 e951.
11. Respiratory Syncytial Virus (RSV) Season, U.S. 2010-2011. http://www.cdc. gov/rsv/research/us-surveillance.html. Accessed November 11, 2011.
12. Highlights of Synagis (palivizumab) prescribing information. www. medimmune.com/pdf/products/synagis_pi.pdf. Accessed November 11, 2011.
13. American Thoracic Society: Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003, 168:356-396.
14. Centers for Medicare and Medicaid Services. National summary of medicaid managed care programs and enrollment as of July 1, 2010. https:/www.cms.gov/MedicaidDataSourcesGenInfo/06_DescStateProg.asp. Accessed November 11, 2011.
15. Winterstein AG, Hampp C, Saidi A: Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf 2012, 21(1):53-60.
16. Gooch K, Busch K, Khong H: Length of hospital stay for respiratory syncytial virus in prophylaxed versus non-prophylaxed infants. In 29th Annual Meeting of the European Society for Paediatric Infectious Diseases. The Hague, The Netherlands; 2011.
17. American Academy of Pediatrics: Respiratory Syncytial Virus. In Red Book: 2009 Report of the Committee on Infectious Diseases. 28th edition. Edited by Pickering LK BC, Kimberlin DW, Long SS. Elk Grove Village, IL: American Academy of Pediatrics; 2009.